Yoichi Araki

• Position: Postdoctoral fellow

• Hometown: Yokohama, Japan

• Research Project: SynGAP in Health and Diseases.

• Publications:

  1. Araki Y, Zeng ML, Zhang M, & Huganir RL. Rapid dispersion of SynGAP from synaptic spines triggers AMPA receptor insertion and spine enlargement during LTP. Neuron. 85(1):173-189 (2015).

  2. Hayashi-Takagi A, Araki Y, Nakamura M, Vollrath B, Duron SG, Yan Z, Kasai H, Huganir RL, Campbell DA, & Sawa A.  PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proceedings of the National Academy of Sciences of the United States of America. 111(17):6461-6466 (2014).

  3. Mihalas AB, Araki Y, Huganir RL, & Meffert MK.  Opposing action of nuclear factor kappaB and Polo-like kinases determines a homeostatic end point for excitatory synaptic adaptation.  Journal of Neuroscience. 33(42):16490-16501 (2013).

  4. Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, Higashi K, Park AR, Spiegelman D, Dobrzeniecka S, Piton A, Tomitori H, Daoud H, Massicotte C, Henrion E, Diallo O, Shekarabi M, Marineau C, Shevell M, Maranda B, Mitchell G, Nadeau A, D'Anjou G, Vanasse M, Srour M, Lafreniere RG, Drapeau P, Lacaille JC, Kim E, Lee JR, Igarashi K, Huganir RL, Rouleau GA, & Michaud JL.  Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. American Journal of Human Genetics. 88(3):306-316 (2011).

  5. Hata S, Fujishige S, Araki Y, Taniguchi M, Urakami K, Peskind E, Akatsu H, Araseki M, Yamamoto K, Martins RN, Maeda M, Nishimura M, Levey A, Chung KA, Montine T, Leverenz J, Fagan A, Goate A, Bateman R, Holtzman DM, Yamamoto T, Nakaya T, Gandy S, & Suzuki T.  Alternative processing of gamma-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: evidence for gamma-secretase dysfunction. Annals of Neurology. 69(6):1026-1031 (2011).

  6. Araki Y, Lin DT, & Huganir RL.  Plasma membrane insertion of the AMPA receptor GluA2 subunit is regulated by NSF binding and Q/R editing of the ion pore. Proceedings of the National Academy of Sciences of the United States of America. 107(24):11080-11085 (2010).

  7. Hata S, Fujishige S, Araki Y, Kato N, Araseki M, Nishimura M, Hartmann D, Saftig P, Fahrenholz F, Taniguchi M, Urakami K, Akatsu H, Martins RN, Yamamoto K, Maeda M, Yamamoto T, Nakaya T, Gandy S, & Suzuki T.  Alcadein cleavages by amyloid beta-precursor protein (APP) alpha- and gamma-secretases generate small peptides, p3-Alcs, indicating Alzheimer disease-related gamma-secretase dysfunction. J Biol Chem. 284(52):36024-36033 (2009).

  8. Araki Y, Kawano T, Taru H, Saito Y, Wada S, Miyamoto K, Kobayashi H, Ishikawa HO, Ohsugi Y, Yamamoto T, Matsuno K, Kinjo M, & Suzuki T.  The novel cargo Alcadein induces vesicle association of kinesin-1 motor components and activates axonal transport. EMBO J. 26(6):1475-1486 (2007).

  9. Suzuki T, Araki Y, Yamamoto T, & Nakaya T.  Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis. J Biochem. 139(6):949-955(2006).

  10. Araki Y, Miyagi N, Kato N, Yoshida T, Wada S, Nishimura M, Komano H, Yamamoto T, De Strooper B, Yamamoto K, & Suzuki T.  Coordinated metabolism of Alcadein and amyloid beta-protein precursor regulates FE65-dependent gene transactivation. J Biol Chem. 279(23):24343-24354 (2004).

  11. Araki Y, Tomita S, Yamaguchi H, Miyagi N, Sumioka A, Kirino Y, & Suzuki T.  Novel cadherin-related membrane proteins, Alcadeins, enhance the X11-like protein-mediated stabilization of amyloid beta-protein precursor metabolism. J Biol Chem. 278(49):49448-49458 (2003).